Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

CARMESilk Chemotherapy-induced Alopecia - Relief Managed by Engineered Silk

Coordinator
Friedrich-Schiller-Universität Jena, Germany
Runs
1 October 2025 to 30 September 2028
Status
Running
EU funding
€401k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101211467

What the project is doing

In the project's own words, from its summary on CORDIS.

This research project, CARMESilk, aims to develop an innovative solution for preventing chemotherapy-induced alopecia (CIA) to improve cancer patients' quality of life. CIA is one of the most distressing side effects of cancer, affecting up to 65% of cancer patients undergoing treatment, causing social withdrawal, decreased self-esteem, and depression. Doxorubicin, a chemotherapeutic agent from the group of anthracyclines, is used as cancer drug in breast, ovary, bladder, and thyroid cancers, among others, and it has an incidence of CIA of 60-100%.

Current therapies focus mainly on scalp cooling technology with limited availability, high cost, long-time treatment, and not recommended for children. For this reason, the development of effective CIA prevention technologies has the potential to be truly life-changing for cancer patients by alleviating the psychological distress associated with treatment and by empowering patients to maintain a sense of normalcy and control during a challenging period.

CARMESilk, aims to create a novel, patient-friendly technology, silk fibroin-based, that selectively captures doxorubicin within the hair matrix, via minimally invasive routes, thereby preventing hair loss while still maintaining chemotherapy efficacy. The fabrication of a 3D bioprinted scalp model using human hair follicles will establish the way for personalized CIA prevention strategies. CARMESilk is an interdisciplinary project combining nanotechnology, materials science, and bioengineering with a patient-centric approach.

The project, as a Global fellowship, will be performed over three years, in US (2 years) and in Germany (1 year), with experts in the tissue engineering field. The achievement of CARMESilk goals will represent an improvement in patients' quality of life, a proof of concept of the technology that can be applied to other chemotherapy agents, highly impacting CIA prevention during an already challenging period.

Topics

Who is involved

OrganisationCityCountryRole
Friedrich-Schiller-Universität JenaJenaGermanyCoordinator
Trustees of Tufts College Non Profit CorporationMedford MaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI